Single-Pill HIV Regimen Matches Complex Multi-Drug Therapy in Trial of Long-Term Survivors

For most people living with HIV today, treatment has been consolidated into a single daily pill. That milestone, reached progressively over the past two decades, represents one of the most consequential advances in the history of infectious disease management. But a subset of patients - mostly those diagnosed in the early years of the epidemic who accumulated resistance to first-generation antiretrovirals over decades of treatment - has remained on complex multi-tablet regimens, sometimes taking three to eleven pills per day.

A phase 3 clinical trial led by Professor Chloe Orkin of Queen Mary University of London now offers those patients a potential path to simplification. The ARTISTRY-1 trial, presented at the Conference on Retroviruses and Opportunistic Infections 2026 in Denver and published simultaneously in The Lancet, tested a single daily tablet combining bictegravir (BIC) and lenacapavir (LEN) against participants' existing complex regimens.

Who Was in the Trial

The trial's demographics are notable. The median age of its 550+ participants across 15 countries was 60 years - the oldest median age of any HIV treatment registration trial conducted to date. Participants had been taking HIV treatment for a median of 28 years. Most were taking at least three pills per day, with a maximum of eleven. Approximately 80% had documented resistance to prior HIV therapies, and most carried at least one additional health condition - cardiovascular disease, kidney disease, or both - alongside their HIV diagnosis.

This is a population for whom drug interactions pose a genuine clinical hazard. Multi-drug HIV regimens interact with statins, antihypertensives, and other medications commonly prescribed for age-related conditions. Reducing the complexity of the HIV regimen reduces interaction risk.

Efficacy and Safety Outcomes

Nearly 96% of participants who switched to the BIC/LEN single tablet maintained viral suppression - HIV levels below 50 copies per milliliter - during the trial. That rate was similar to participants who continued their existing complex regimens, which also maintained suppression at around 94 to 96%. No new drug resistance emerged in the BIC/LEN group.

Lipid profiles improved among participants who switched. For a population already at elevated cardiovascular risk due to age, long-term HIV infection, and prior antiretroviral therapy, improving lipid parameters through treatment simplification represents a meaningful secondary benefit. No significant or novel safety concerns were identified. Participants self-reported the new regimen as easier and more convenient to take.

What Comes Next

ARTISTRY-1 was a registration trial designed to establish efficacy and safety over its follow-up period. Additional clinical trials are underway to confirm long-term safety and effectiveness of the BIC/LEN combination. Lenacapavir, a capsid inhibitor with a mechanism distinct from most existing drugs, requires continued monitoring for long-term interaction profiles.

"Simplifying HIV treatment from handfuls of pills at the start of the epidemic to one pill a day has improved clinical outcomes for most people living with HIV," said Orkin. "However, until now, some people with resistant virus or clinical contraindications cannot take these simpler regimens and must instead take complex regimens which may place them at risk of drug interactions."